These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 18448284)

  • 1. Liposomal bismuth-ethanedithiol formulation enhances antimicrobial activity of tobramycin.
    Halwani M; Blomme S; Suntres ZE; Alipour M; Azghani AO; Kumar A; Omri A
    Int J Pharm; 2008 Jun; 358(1-2):278-84. PubMed ID: 18448284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bismuth-thiol incorporation enhances biological activities of liposomal tobramycin against bacterial biofilm and quorum sensing molecules production by Pseudomonas aeruginosa.
    Halwani M; Hebert S; Suntres ZE; Lafrenie RM; Azghani AO; Omri A
    Int J Pharm; 2009 May; 373(1-2):141-6. PubMed ID: 19429299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bismuth-ethanedithiol incorporated in a liposome-loaded tobramycin formulation modulates the alginate levels in mucoid Pseudomonas aeruginosa.
    Alipour M; Dorval C; Suntres ZE; Omri A
    J Pharm Pharmacol; 2011 Aug; 63(8):999-1007. PubMed ID: 21718282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of liposomal bismuth-ethanedithiol-loaded tobramycin after intratracheal administration in rats with pulmonary Pseudomonas aeruginosa infection.
    Alhariri M; Omri A
    Antimicrob Agents Chemother; 2013 Jan; 57(1):569-78. PubMed ID: 23147741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity and synergy of bismuth thiols and tobramycin against Burkholderia cepacia complex.
    Veloira WG; Domenico P; LiPuma JJ; Davis JM; Gurzenda E; Kazzaz JA
    J Antimicrob Chemother; 2003 Dec; 52(6):915-9. PubMed ID: 14585856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Attenuation of Pseudomonas aeruginosa virulence factors and biofilms by co-encapsulation of bismuth-ethanedithiol with tobramycin in liposomes.
    Alipour M; Suntres ZE; Lafrenie RM; Omri A
    J Antimicrob Chemother; 2010 Apr; 65(4):684-93. PubMed ID: 20159770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-encapsulation of gallium with gentamicin in liposomes enhances antimicrobial activity of gentamicin against Pseudomonas aeruginosa.
    Halwani M; Yebio B; Suntres ZE; Alipour M; Azghani AO; Omri A
    J Antimicrob Chemother; 2008 Dec; 62(6):1291-7. PubMed ID: 18931388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro interactions of tobramycin with various nonantibiotics against Pseudomonas aeruginosa and Burkholderia cenocepacia.
    Treerat P; Widmer F; Middleton PG; Iredell J; George AM
    FEMS Microbiol Lett; 2008 Aug; 285(1):40-50. PubMed ID: 18513356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bactericidal efficacy of liposomal aminoglycosides against Burkholderia cenocepacia.
    Halwani M; Mugabe C; Azghani AO; Lafrenie RM; Kumar A; Omri A
    J Antimicrob Chemother; 2007 Oct; 60(4):760-9. PubMed ID: 17673475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibacterial activity of liposomal gentamicin against Pseudomonas aeruginosa: a time-kill study.
    Rukholm G; Mugabe C; Azghani AO; Omri A
    Int J Antimicrob Agents; 2006 Mar; 27(3):247-52. PubMed ID: 16472992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liposome-encapsulated antibiotics: preparation, drug release and antimicrobial activity against Pseudomonas aeruginosa.
    Lagacé J; Dubreuil M; Montplaisir S
    J Microencapsul; 1991; 8(1):53-61. PubMed ID: 1908898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antimicrobial effectiveness of liposomal polymyxin B against resistant Gram-negative bacterial strains.
    Alipour M; Halwani M; Omri A; Suntres ZE
    Int J Pharm; 2008 May; 355(1-2):293-8. PubMed ID: 18164881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of breakpoint combination sensitivity testing as a simple and convenient method to evaluate the combined effects of ceftazidime and tobramycin on Pseudomonas aeruginosa and Burkholderia cepacia complex isolates in vitro.
    Tunney MM; Scott EM
    J Microbiol Methods; 2004 Apr; 57(1):107-14. PubMed ID: 15003693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of tobramycin incorporated with bismuth-ethanedithiol loaded on niosomes on the quorum sensing and biofilm formation of Pseudomonas aeruginosa.
    Mahdiun F; Mansouri S; Khazaeli P; Mirzaei R
    Microb Pathog; 2017 Jun; 107():129-135. PubMed ID: 28323149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of doripenem against Pseudomonas aeruginosa and Burkholderia cepacia isolates from both cystic fibrosis and non-cystic fibrosis patients.
    Traczewski MM; Brown SD
    Antimicrob Agents Chemother; 2006 Feb; 50(2):819-21. PubMed ID: 16436756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liposome-mediated gentamicin delivery: development and activity against resistant strains of Pseudomonas aeruginosa isolated from cystic fibrosis patients.
    Mugabe C; Azghani AO; Omri A
    J Antimicrob Chemother; 2005 Feb; 55(2):269-71. PubMed ID: 15590716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interaction between tobramycin and CSA-13 on clinical isolates of Pseudomonas aeruginosa in a model of young and mature biofilms.
    Nagant C; Tré-Hardy M; El-Ouaaliti M; Savage P; Devleeschouwer M; Dehaye JP
    Appl Microbiol Biotechnol; 2010 Sep; 88(1):251-63. PubMed ID: 20625718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimicrobial efficacy of tobramycin polymeric nanoparticles for Pseudomonas aeruginosa infections in cystic fibrosis: formulation, characterisation and functionalisation with dornase alfa (DNase).
    Deacon J; Abdelghany SM; Quinn DJ; Schmid D; Megaw J; Donnelly RF; Jones DS; Kissenpfennig A; Elborn JS; Gilmore BF; Taggart CC; Scott CJ
    J Control Release; 2015 Jan; 198():55-61. PubMed ID: 25481442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of antibiotic co-administration on young and mature biofilms of cystic fibrosis clinical isolates: the importance of the biofilm model.
    Tré-Hardy M; Macé C; El Manssouri N; Vanderbist F; Traore H; Devleeschouwer MJ
    Int J Antimicrob Agents; 2009 Jan; 33(1):40-5. PubMed ID: 18801647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and potential for resistance selection of antipseudomonal treatments in a mouse model of lung infection by hypermutable Pseudomonas aeruginosa.
    Maciá MD; Borrell N; Segura M; Gómez C; Pérez JL; Oliver A
    Antimicrob Agents Chemother; 2006 Mar; 50(3):975-83. PubMed ID: 16495260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.